Szewczuk, Myron R - Queen's University - Department of Biomedical and Molecular Sciences

个人简介

B.Sc. (Hons.) 1971 - University of Guelph; Physical chemistry MSc 1972 - University of Guelph; Biochemistry and thermodynmics of protein-protein interactions. Supervisor - Dr. Rattray PhD 1974- University of Windsor; Biology and immunochemistry. Supervisor - Dr. T.K. Mukkur Killiam Post-doctoral Research Scholar - Cornell University Medical College, New York City, U.S.A. Cellular immunology, with Dr. Greg Siskind (01/1975 - 05/1977). NIH Post-doctoral Research Scholar - Cornell University Medical College, New York City, U.S.A. Cellular immunology, with Dr. Greg Siskind (05/1977 - 06/1978). Research Associate - Cornell University Medical College, New York City, U.S.A. Aging of the immune system, with Drs. Greg Siskind and Marc Weksler (09/1975 - 06/1978).

研究领域

1.) Alternate therapeutic treatment of cancer. 2.) The role of glycosylation in the activation of neurotrophin Trk, EGFR, insulin and TOLL-like receptors. 3.) Molecular basis of Neu1 sialidase underlying TOLL-like receptor activation in pathophysiology of infections and inflammation. 4.) N-Acylated Hexosamines as Nutraceuticals: From Shellfish to Algae to Mammalian Bone and Joint Health. 5.) Trypanosome trans-sialidase for neuronal differentiation and neuroprotection from apoptosis

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Manpreet Sambi, Sabah Haq, Vanessa Samuel, Bessi Qorri, Fiona Haxho, Kelli Hill, William Harless and Myron R. Szewczuk. Alternative therapies for metastatic breast cancer: multimodal approach targeting tumor cell hetereogeneity. Breast Cancer - Targets and Therapy 2017:9 1–9. Received 23rd December 2016, Accepted 15th February 2017 as it stands in current form. Manpreet Sambi and Myron R. Szewczuk. KRAS mutations: efficacy and sensitivity of early predictive screening of cancer progression require other gene mutations in addition to KRAS. Translational Cancer Research 2017. Received 8th December 2016, Accepted 11th December 2016 as it stands in current form. DOI: http://dx.doi.org/10.21037/tcr.2017.01.05 Xia Li, Myron R. Szewczuk and Cecile Malardier-Jugroot. Folic acid conjugated amphiphilic alternating copolymer as a new active tumor targeting drug delivery platform. Drug Design, Development and Therapy 2016:10 1–10. DOI https://doi.org/10.2147/DDDT.S123386 Roman Akasov, Sabah Haq, Fiona Haxho, Vanessa Samuel, Sergey V. Burov, Elena Markvicheva, Ronald J. Neufeld, and Myron R. Szewczuk. Sialylation transmogrifies human breast and pancreatic cancer cells into 3D multicellular tumor spheroids using cyclic RGD peptide induced self-assembly. 2016 Oncotarget 2016, Vol. 7, No.40 66119-661342016. (impact factor 6.4) Received: June 21, 2016 Accepted: August 25, 2016. DOI:10.18632/oncotarget.11868 Fiona Haxho, Ronald J. Neufeld and Myron R. Szewczuk. Neuraminidase-1: A novel therapeutic target in multistage tumorigenesis. Oncotarget 2016, Vol. 7, No. 26, pages 40860-40881. (impact factor 6.4) Received: March 01, 2016 Accepted: March 18, 2016 Published: March 27, 2016. DOI: 10.18632/oncotarget.8396 Vitaliy Kapishon, Stephanie Allison, Ralph A. Whitney, Michael F. Cunningham, Myron R. Szewczuk and Ronald J. Neufeld. Oseltamivir-conjugated polymeric micelles prepared by RAFT living radical polymerization as a new active tumor targeting drug delivery platform. Biomater. Sci., 2016, 4, 51. Received 9th November 2015, Accepted 11th January 2016 DOI: 10.1039/c5bm00519a Michael Hrynyk, Jordon P. Ellis, Fiona Haxho, Stephanie Allison, Joseph A.M. Steele, Samar Abdulkhalek, Ronald J. Neufeld and Myron Szewczuk. Therapeutic designed poly (lactic-co-glycolic acid) cylindrical oseltamivir phosphate loaded implants impede tumor neovascularization, growth and metastasis in mouse model of human pancreatic carcinoma. Drug Design, Development and Therapy 2015:9 4573-4586 . Received 9 June 2015, Accepted 2 July 2015, Published 10 August 2015. Open access - Metrics views 658 since 10/08/2015 to 26/08/2015. DOI http://dx.doi.org/10.2147/DDDT.S90170 Schammim Ray Amith, Samar Abdulkhalek and Myron R. Szewczuk. Role of Glycosylation in TOLL-like Receptor Activation and Pro-inflammatory Responses. Textbook, Glycobiology and Diseases: Chapter 9, pages 165-185 © 2016 by Taylor & Francis Group, LLC Fiona Haxho, Stephanie Allison, Farah Alghamdi, Lacey Brodhagen, Victoria EL Kuta, Samar Abdulkhalek, Ronald J Neufeld, and Myron R Szewczuk. Oseltamivir phosphate monotherapy ablates tumor neovascularization, growth, and metastasis in mouse model of human triple-negative breast adenocarcinoma. Breast Cancer: Targets and Therapy 2014: 6 191-203. Received 23 September 2014, Accepted 10 October 2014, Published 9 December 2014. DOI http://dx.doi.org/10.2147/BCTT.S74663 Fiona Haxho, Farah Alghamdi, Ronald J Neufeld and Myron R Szewczuk. Novel Insulin Receptor-Signaling Platform. Int J Diabetes Clin Res; Review Article 2014 IJDCR-1-005 (Vol 1, issue 1). Received: October 09, 2014: Accepted: October 27, 2014: Published: October 30, 2014; DOI: http://clinmedlibrary.com/articles/ijdcr/ijdcr-1-005.pdf Samar Abdulkhalek, Olivia D Geen, Lacey Brodhagen, Fiona Haxho, Farah Alghamdi, Stephanie Allison, Duncan J Simmons, Leah K O’Shea, Ronald J Neufeld and Myron R Szewczuk. Transcriptional factor snail controls tumor neovascularization, growth and metastasis in mouse model of human ovarian carcinoma. Clinical and Translational Medicine 2014, 3:28. Received: 21 June 2014, Accepted: 24 July 2014, Published:23 September 2014. Article metric: 1306 total accesses; DOI: http://10.1186/s40169-014-0028-z Farah Alghamdi, Merry Guo, Samar Abdulkhalek, Nicola Crawford, Schammim Ray Amith and Myron R. Szewczuk. A novel insulin receptor-signaling platform and its link to insulin resistance and type 2 diabetes. Cellular Signalling 26 (2014) 1355–1368, (open access) submitted Feb08, 2014 accepted Feb23, 2014 as it stands (Impact factor: 4.3). DOI: http://dx.doi.org/10.1016/j.cellsig.2014.02.015 O’Shea LK, Abdulkhalek S, Allison S, Neufeld RJand Szewczuk MR.Therapeutic targeting of Neu1 sialidase with oseltamivir phosphate (Tamiflu®) disables cancer cell survival in human pancreatic cancer with acquired chemoresistance. OncoTargets and Therapy 2014:7 117–134. Published 14 January 2014 (Open access: Total articles views: 1219 to March 8, 2014} DOI: http://dx.doi.org/10.2147/OTT.S55344